CYP1B1

Cytochrome P450 1B1 · Q16678 · CYP1B1 on Sugi Atlas →

195,033 patent compounds predicted against CYP1B1, 107,593 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL77179	0.61	16/20
SCHEMBL75348	0.51	15/20
Alpha-Naphthoflavone (SCHEMBL121594)	1.00	14/20
SCHEMBL113300	0.55	11/20
SCHEMBL113301	0.55	11/20
Chalcone (SCHEMBL27580)	1.00	10/20
Chalcone (SCHEMBL27581)	1.00	10/20
SCHEMBL77498	1.00	10/20
SCHEMBL96291	0.70	9/20
SCHEMBL83267	0.56	9/20
SCHEMBL83322	0.56	9/20
Mitoflaxone (SCHEMBL106705)	0.56	8/20
SCHEMBL82827	0.49	8/20
SCHEMBL98657	0.48	8/20
Kaempferol (SCHEMBL18817)	1.00	7/20
Myricetin (SCHEMBL19302)	1.00	7/20
Apigenin (SCHEMBL19428)	1.00	7/20
Quercetin (SCHEMBL19723)	1.00	7/20
Galangin (SCHEMBL117225)	1.00	7/20
Quercetin (SCHEMBL118425)	1.00	7/20

Clinical trials — most relevant to CYP1B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
Role of Antioxidants Supplementation in Chronic Pancreatitis	PHASE3	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
NCCH2006/MK010 Trial (FORTUNE Trial)	PHASE2	RECRUITING
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis	PHASE2	ACTIVE_NOT_RECRUITING
Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56	PHASE2	COMPLETED
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease	PHASE1	COMPLETED
Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects	PHASE1	COMPLETED
A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects	PHASE1	COMPLETED
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)	PHASE1	COMPLETED
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers	PHASE1	COMPLETED
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis	PHASE1	RECRUITING
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
Connecting Breath and Mind for CYP With Long COVID	nan	UNKNOWN
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED
Impact of OCT1 and CYP2D6 Genotypes on Pharmacokinetics of Berberine in Healthy Volunteers	nan	COMPLETED
CYP2C19 Variants and Limonene Metabolism	nan	RECRUITING
The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis	nan	UNKNOWN
Cyclophosphamide in Lupus Nephritis	nan	UNKNOWN
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics	nan	COMPLETED
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
Effects of Genotype on CYP2C9 Drug Interactions	nan	COMPLETED
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment	nan	RECRUITING
CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP1B1 binder may also engage these)

Protein	Name	Similarity
Q64678	—	1.000	Q64678 →
Q64429	—	0.999	Q64429 →
P24453	—	0.980	P24453 →
P05176	—	0.980	P05176 →
Q9VW43	—	0.979	Q9VW43 →
Q9VWR5	—	0.979	Q9VWR5 →
P00186	—	0.979	P00186 →
P04799	—	0.978	P04799 →
P70085	—	0.977	P70085 →
Q64391	—	0.977	Q64391 →
Q0IIF9	—	0.977	Q0IIF9 →
P56592	—	0.977	P56592 →
P98181	—	0.977	P98181 →
P30437	—	0.977	P30437 →
O35084	—	0.976	O35084 →
Q6R7M4	—	0.976	Q6R7M4 →
Q5RBQ1	—	0.976	Q5RBQ1 →
Q3LFT9	—	0.976	Q3LFT9 →
Q5KQT6	—	0.976	Q5KQT6 →
O65012	—	0.973	O65012 →
Q00557	—	0.973	Q00557 →
P12394	—	0.973	P12394 →
Q3MID2	—	0.973	Q3MID2 →
P00187	—	0.972	P00187 →
B2RXA7	—	0.971	B2RXA7 →
Q92148	—	0.971	Q92148 →
O77810	—	0.971	O77810 →
O18992	—	0.970	O18992 →
Q3LFU0	—	0.970	Q3LFU0 →
O93323	—	0.970	O93323 →